S.BIOMEDICS

Treatment of Stroke CF-TED-N Secretome of Embryonic Stem Cell-derived PSA-NCAM positive Neural Precursor Cells

Stroke: Neurological disease with abnormal cerebral blood flow that causes local cell loss

Cause: It is caused as the brain tissues are unable to obtain oxygen and nutrients due to poor blood supply to certain parts of the brain.
Symptom: It may result in a severe headache and accompany vomiting, dizziness, or changes in the consciousness state.
Paralysis or numbness in the limbs or face; a sense of balance may be lost

Basic Research	Non- clinical	Phase 1	Phase 2	Phase 3	Approval
Candidate discovery

DATA

Secretion of Active Ingredients: Stroke indicators and active ingredients such as midkine, VEGF, and TGF-β are included.

Ischemic Lesion Improvement

Stroke was induced by ligation of the middle cerebral artery in the model animals, and the damage induced as such mainly occurred in the cortical and striatal regions of the right brain. A single dose of CF-TED-N to the model animals with stroke showed that the ischemic lesion area was reduced after 14 days.

Control

Vehicle

CF-TED-N

Behavioral Recovery: After the administration of CF-TED-N to model animals, a statistically significant behavioral improvement effect was found in the beam balance test and prehensile traction test compared to the control group; improvement was also found in the line-cross test that measures the decrease of foot faults and activity per unit time. In particular, immediate effects after administration are expected as the improvement effect was confirmed from Day 3 of CF-TED-N treatment in the beam balance test.